Skip to main content
HLS Therapeutics Inc. logo

HLS Therapeutics Inc. — Investor Relations & Filings

Ticker · HLS ISIN · US40390B3078 LEI · 549300QKXFY1J71L2D68 TSX Wholesale and retail trade
Open in API
Filings indexed 189 across all filing types
Latest filing 2025-03-13 Earnings Release
Country CA Canada
Listing TSX HLS

About HLS Therapeutics Inc.

https://hlstherapeutics.com/

HLS Therapeutics Inc. is a specialty pharmaceutical company focused on the acquisition and commercialization of branded medicines across North America. The company targets products that address unmet needs, primarily in the treatment of psychiatric disorders and cardiovascular disease/risk reduction. Its commercial-stage portfolio includes CLOZARIL® (clozapine) for psychiatric disorders and VASCEPA® (icosapent ethyl) for cardiovascular risk reduction. HLS also commercializes NILEMDO® (bempedoic acid) and NEXLIZET® (bempedoic acid/ezetimibe combination) for the reduction of LDL-cholesterol in patients at risk of cardiovascular disease. HLS ensures reliable market access to these essential therapies by sourcing products directly from originators and best-in-class manufacturing partners.

Recent filings

Filing Released Lang Actions
News release (section 4.8 of NI 62-104).pdf
Earnings Release Classification · 1% confidence The document is a press release announcing the company’s fourth quarter and full fiscal 2024 financial results, including revenue, EBITDA, net loss, cash flow highlights, outlook guidance, plus an announcement of a normal course issuer bid and details of a conference call. This format and content—key quarterly and annual financial metrics, management commentary, and Q&A call details—matches an Earnings Release (ER) rather than a full annual report or MD&A. It is not simply an announcement of publication but the primary financial results communication. FY 2024
2025-03-13 English
News release - English.pdf
Board/Management Information Classification · 1% confidence The document is a press release announcing the appointment of a new member to the company’s Board of Directors. It details a governance change (new board director) rather than financial results, AGM materials, or other filings. This fits the Board/Management Information category.
2025-03-13 English
News release - English.pdf
Report Publication Announcement Classification · 1% confidence The document is a short announcement (under 5k characters) stating the date and details for the upcoming release of Q4 and fiscal 2024 financial results and the related conference call. It does not contain the actual financial results, transcript, or presentation materials; rather, it notifies investors when and how the report and call will occur. This fits the definition of a Report Publication Announcement (RPA) under the “menu vs meal” rule.
2025-02-27 English
News release - English.pdf
Regulatory Filings
2024-10-24 English
News release - English.pdf
Regulatory Filings
2024-07-25 English
News release - English.pdf
Regulatory Filings
2024-07-02 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.